SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
January 24, 2002
----------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
--------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
---------------------
(Address of principal executive offices)
(631) 962-2000
--------------
(Registrant's telephone number, including area code)
N/A
-------------------------------
(Former name or former address,
if changed since last report.)
ITEM 5. OTHER EVENTS
On January 24, 2002, OSI Pharmaceuticals, Inc., a Delaware
corporation, issued a press release, a copy of which is attached hereto
as Exhibit 99 and incorporated herein by reference.
ITEM 7. EXHIBITS
- ---------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
- ---------------------------------------------------------------------
99 Press release, dated January 24, 2002.
- ---------------------------------------------------------------------
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: January 24, 2002 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-----------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
- ---------------------------------------------------------------------
EXHIBIT NO. DESCRIPTION
- ---------------------------------------------------------------------
99 Press release, dated January 24, 2002.
- ---------------------------------------------------------------------